Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/matk) is investigating potential claims against the board of directors of Martek Biosciences Corp. ("Martek" or the "Company") (NASDAQ: MATK) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell Martek to Royal DSM N.V. in a transaction valued at approximately $1.087 billion.

Our investigation concerns possible breaches of fiduciary duty and other violations of law related to the approval of the transaction by Company’s board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of Martek. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/matk.

Under the terms of the definitive agreement, Martek shareholders are to receive $31.50 in cash for each share they own.

If you own shares of Martek and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/matk. You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com. For more information about class action cases in general, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

Martek (NASDAQ:MATK)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Martek.
Martek (NASDAQ:MATK)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Martek.